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Abstract
Background: The soluble epoxide hydrolase (sEH) is an important enzyme chiefly involved in the metabolism
of fatty acid signaling molecules termed epoxyeicosatrienoic acids (EETs). sEH inhibition (sEHI) has proven to be
protective against experimental cerebral ischemia, and it is emerging as a therapeutic target for prevention and
treatment of ischemic stroke. However, the role of sEH on synaptic function in the central nervous system is still largely
unknown. This study aimed to test whether sEH C-terminal epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)
dodecanoic acid (AUDA) affects basal synaptic transmission and synaptic plasticity in the prefrontal cortex area (PFC).
Whole cell and extracellular recording examined the miniature excitatory postsynaptic currents (mEPSCs) and field
excitatory postsynaptic potentials (fEPSPs); Western Blotting determined the protein levels of glutamate receptors
and ERK phosphorylation in acute medial PFC slices.
Results: Application of the sEH C-terminal epoxide hydrolase inhibitor, AUDA significantly increased the amplitude of
mEPSCs and fEPSPs in prefrontal cortex neurons, while additionally enhancing long term potentiation (LTP). Western
Blotting demonstrated that AUDA treatment increased the expression of the N-methyl-D-aspartate receptor (NMDA)
subunits NR1, NR2A, NR2B; the α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor subunits GluR1,
GluR2, and ERK phosphorylation.
Conclusions: Inhibition of sEH induced an enhancement of PFC neuronal synaptic neurotransmission. This enhancement
of synaptic neurotransmission is associated with an enhanced postsynaptic glutamatergic receptor and postsynaptic
glutamatergic receptor mediated synaptic LTP. LTP is enhanced via ERK phosphorylation resulting from the delivery of
glutamate receptors into the PFC by post-synapse by treatment with AUDA. These findings provide a possible link
between synaptic function and memory processes.
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Background
A ubiquitous bifunctional vertebrate enzyme, soluble ep-
oxide hydrolase (sEH), is comprised of a C-terminal ep-
oxide hydrolase (EH) domain and an N-terminal lipid
phosphatase (PT) domain, and is widely distributed in a
variety of mammalian organs and tissues such as liver,
vascular endothelium, kidney [1–5]. Soluble epoxide
hydrolase (sEH) is the major key regulator involved in
the epoxyeicosatrienoic acids (EETs) metabolism effects
[6]. Inhibition of sEH metabolism through pharmaco-
logical inhibition, or genetic deletion, has been shown to
effectively increase endogenous EET levels. Due to this
activity, sEH inhibitors are being developed as antihyper-
tensive agents to prevent cardiac hypertrophy, inflamma-
tion and hyperglycemia in diabetic mice [7–10]. Thus
sEH inhibition (sEHI) can have a somewhat similar
effect to EET augmentation.
In the brain, sEH distributed in the cortex, striatum,
hypothalamus and brain stem regions [11, 12]. The sEH
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is expressed in neural tissue and cerebral arterioles [2, 11, 13].
Immunohistochemistry technique observed that sEH is co-
localized with neuron in cerebral cortex and striatum in the
stroke brain [4]. Several animal studies, sEH activity and sEH-
EET pathway has been implicated in the disease associated
neurotransmission imbalance such as anxiety-related behavior
and seizure disorder [14–16]. Electrophysiology studies dem-
onstrated that the C-terminal epoxide hydrolase (EH) inhibi-
tor 12-(3-adamantan-1-yl-ureido) dodecanoic acid (AUDA) is
similarly elevated the endogenous EETs to increase neuronal
activity in the hypothalamus and brain stem of SHR rats [12].
The 5,6-EET increases the spontaneous excitatory postsynap-
tic current (sEPSC) frequency in spinal cord slices to affect
the pain sensitivity [17]. Together, these studies raise the pos-
sibility that the EETs could modulate the physiological actions
through the enhancement of excitatory neurotransmit-
ter and neuronal activity. However, how the sEH-EET
affect the basal levels of glutamate within prefrontal
cortex remain unclear.
Glutamate, which is recognized as the major excitatory
neurotransmission in the CNS [18], is involved in basal
neurotransmission, synaptic plasticity, learning, and mem-
ory [19–21]. Activity dependent long term potentiation in-
creases synaptic strength and requires a contribution from
postsynaptic receptors such as α-Amino-3-hydroxy-5-me-
thyl-4-isoxazolepropionic acid (AMPA) receptors and N-
methyl-D-aspartate receptor (NMDA) receptors [22, 23].
NMDA receptor activation induces Ca2+ influx and
triggers Ca2+/calmodulin-dependent protein kinase II
(CaMKII) thereby enhancing synaptic strength [24,
25]. Mitogen-activated protein kinase (MAPK) and
phophatidylinositol-3kinase (PI3K) are both impli-
cated in long term potentiation (LTP) and cognitive
learning [26–28]. The AMPA receptor trafficking de-
livery mechanism to synaptic membranes plays an
important role in LTP [29, 30]. However, the effect
and mechanisms by which sEH inhibitor, AUDA
modulates synaptic plasticity remain unclear.
In current study, we aimed to test whether AUDA af-
fects basal synaptic transmission and synaptic plasticity.
Firstly, we determined the effects of AUDA on gluta-
matergic neurotransmission and synaptic efficacy in
prefrontal cortex. Secondly, we further determined the ex-
pression of glutamate receptors and mechanisms under-
lying the AUDA-induced alteration in neurophysiology
function. Finally, we wished to explore the possible signal
pathway underlying AUDA-mediated enhancement of
PFC glutamatergic neurotransmission. Here we found that
the AUDA induces the enhancement of synaptic transmis-
sion, LTP and glutamate receptors in the prefrontal
cortex. The sEH inhibition may increase the levels of EETs
with subsequent activation of extracellular-signal-regulated




All procedures have been approved by the Institutional
Animal Care and Use Committee of the College of Medi-
cine, National Yang-Ming University (Taipei, Taiwan).
Eight weeks old C57BL/6 mice were used in this study
and housed four to a cage in a temperature-controlled
(24 °C) animal colony under a 12:12 light/dark cycle, with
lights on at 7:00 AM. Pelleted chow and water were avail-
able ad libitum. All experimental procedures took place
during the light cycle.
Brain slice preparation and electrophysiological
recordings of the prefrontal cortex
Brain slices (400 μm thickness) were prepared as de-
scribed previously [31]. Whole-cell recordings were
made from the soma of visually-identified pyramidal-like
neurons located in the PFC. Neurons were identified as
projection neurons based on their intrinsic electrophysio-
logical properties [32] in potassium gluconate-containing
electrodes. The miniature excitatory postsynaptic currents
(mEPSCs) were recorded in the presence of bicuculline
(10 μM; Tocris) Tetrodotoxin TTX (1 μM; Tocris). We
also examined paired pulse facilitation (PPF) in slices. The
ratio of the amplitude of the first EPSP (fEPSP1) divided
by the amplitude of the second EPSP (fEPSP2) was exam-
ined at 30 ms, 60 ms, 90 ms and 120-ms inter-pulse inter-
vals. NMDA receptor dependent long term potentiation
was induced by high frequency stimulation (HFS) proto-
cols, 3 times of 1 s, 100Hz stimulus trains separated by a
1 min interval between trains [33].
Drugs
AUDA, (±) 14 (15)- epoxy-5Z, 8Z, 11Z-eicosatrienoic acid
(14,15-EET) and 14,15-epoxyeicosa-5 (Z)-enoic acid
(14,15-EEZE) were obtained from Cayman. The stock so-
lution was prepared in dimethyl sulphoxide (DMSO). The
perused concentration of DMSO did not exceed 0.1 % and
had no effect on basal synaptic transmission. In the
present study, the vehicle control was 0.1 % DMSO in
ACSF.
Western blotting assay
Brain tissues were dissected and lysed in a lysis buffer
containing 1 % Triton X-100, 0.1 % SDS, 50 mM Tris-
HCl, pH 7.5, 0.3 M sucrose, 5 mM EDTA, 2 mM sodium
pyrophosphate, 1 mM sodium orthovanadate, 1 mM enyl-
methylsulfonyl fluoride, supplemented with a complete
protease inhibitor cocktail. Following sonication, lysates
were centrifuged at 12,000 rpm for 30 min to obtain su-
pernatants. The protein concentration of supernatants
was measured using a Bradford assay and equal amount
of protein were separated by SDS-PAGE electrophoresis,
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transferred to Immobilon-P membranes (Millipore). and
incubated in 5 % nonfat dry milk for 60 min. Western blot
analysis used GluR1 (1: 1000; Abcam, Cambridge, UK),
GluR2− (1: 1000; Abcam, Cambridge, UK) and β- Actin
(1:1000; Millipore, Billerica, MA, USA), NR1 (1: 1000;
Abcam, Cambridge, UK), NR2A (1: 1000; Millipore, Biller-
ica, MA, USA) ,NR2B (1: 2000; Millipore, Billerica, MA,
USA), D2 receptor (1: 1000; Millipore, Billerica, MA,
USA,), ERK (1: 2000; Cell signaling Technology, Boston,
MA, USA), p-GluR1 (1: 1000; Abcam, Cambridge, UK), p-
NR2B (1: 1000; Cell signaling Technology, Boston, MA,
USA) antibody, reacted overnight at 4 °C, and then
incubated with HRP-conjugated secondary antibodies
for 1 h at room temperature. Immunoreactivity was
detected by ECL Plus detection reagent (PerkinElmer,
Boston, MA, USA). Films were exposed at different
times to ensure the optimum density but not satu-
rated and followed by densitometry. Protein levels
were first normalized to internal control levels for
each sample and then were measured as fold changes
with respect to controls.
Reverse transcription (RT) and quantitative (q) real-time
polymerase chain reaction (PCR)
Total RNA was isolated using the TRIzol RNA extrac-
tion kit (Invitrogen), and 0.5 μg of RNA was subject
to reverse transcription-PCR with M-MLV (Invitro-
gen). The specific PCR oligonucleotides for these
NMDA and AMPA subunits, and β-actin as internal













The PCR products were separated by 1 % agarose-
gel electrophoresis and visualized with ethidium
bromide staining. Quantitative RT-PCR was carried
out using the StepOnePlus™ Real-Time PCR Systems
and KAPA SYBR FAST qPCR Master Mix according
to the manufacturer's instructions. In brief, β-actin
was used as the internal control for quantitation of
the expression of target genes in samples from vehicle
control vs. AUDA-treated brain tissue.
Statistical analysis
All values are expressed as the mean ± SEM. Electro-
physiology responses and the protein level of vehicle
control and AUDA-exposed group, were assessed
using the Student’s t-test. The stimulus-response
(input–output) relationships, PPF and LTP analyzed
by One-way ANOVA or Two-way ANOVA was
followed with Bonferroni’s post hoc test. The differ-
ence between treated groups was considered signifi-
cant if p < 0.05.
Results
Effects of sEH inhibitor AUDA on prefrontal cortex neurons
We assessed effect of sEHI on both basic neuronal
features and excitatory synaptic transmission in the
PFC. We utilized the protocol that othodromic stim-
uli applied to the layer II of rat prefrontal cortex
slices elicited excitatory postsynaptic currents (EPSCs)
in layer V. Superfusion of AUDA for 10 min resulted
in significantly increased EPSC amplitudes (Fig. 1a).
This result indicated that sEHI enhanced excitatory
synaptic transmission in the PFC. To examine
whether the intrinsic excitability of PFC neurons is
changed by treatment of the sEH inhibitior AUDA,
whole-cell patch clamp recordings were performed on
PFC slices. The pyramidal neurons in layer V neurons
have an average resting membrane potential of -61 ±
1.6 mV and an input resistance of 107 ± 7.8MΩ in
the vehicle control, and an average resting membrane
potential -60 ± 2.3 mV with an input resistance of
111 ± 5.2MΩ after AUDA treatment (n = 5). As shown
in Fig. 1b, there is no difference between the vehicle
control state and AUDA treatment in the number of
action potentials that could be elicited in response to
150-pA depolarizing current pulses. Thus, AUDA treat-
ment cannot significantly alter either the resting membrane
potential or the input resistance. Application of different
concentrations of AUDA, i.e. 1, 5,10 μM enhanced the ini-
tial response of fEPSPs by 138.9 ± 5.8 % (n = 5),184.8 ±
10.2 % (n = 5) and 190 ± 5.8 % (n = 5) of baseline respect-
ively (Fig. 1c). Thus perfusion with 1, 5,10 μM of AUDA
significantly enhanced the fEPSPs compared to vehicle con-
trol (F(3,16) = 36.3 P < 0.001).
Effects of epoxyeicosatrienoic acids (EETs) on prefrontal
cortex neurons
The enhancement of fEPSPs by sEH inhibitor could
be due to its presence and to further promote the
levels of EETs. Thus we determined whether the
14,15-EET produce similar postsynaptic glutamater-
gic neurotransmission effect of AUDA. We found
that fEPSPs was significantly increased during 14,15-
EET-treated (134.2 ± 12.1 %, n = 5 ) of baseline at
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PFC synapse (Fig. 2a). We further examined whether
selective EET antagonist could inhibit the enhance-
ment of fEPSPs by AUDA. The selective EET antag-
onist 14, 15-EEZE (1 μM) (n = 5) combination with
AUDA (5 μM) (n = 5) were added into the PFC slice.
As Shown in Fig. 2b, enhancement of fEPSPs by
AUDA was dramatically inhibited by combining with
14, 15-EEZE at 1 μM 104.2 ± 3.1 %, n = 5). Thus
AUDA induces enhancement of fEPSPs via increas-
ing levels of EETs.
AUDA enhances the I-O efficiency and glutamatergic
transmission at PFC synapses
To determine whether the enhancement of fEPSPs was
due to the alteration of the glutamate neurotransmitter
mediated basal synapse response, we tested the relation-
ship between the strength of a stimulus and its effect on
response (input–output, IO) for fEPSPs in PFC neurons.
The data showed that higher doses of AUDA induced
larger fEPSPs responses which are determined at 2×
threshold than vehicle control state (Fig. 3a). Different
stimulation intensities were applied to observe the amp-
litude of the fEPSPs (Fig. 3b; two-way ANOVA, effect of
treatment F(3,96) = 23.37, p < 0.001; effect of stimulus
intensity F(4,96) = 244.2, p < 0.001; interaction F(12,96) =
14.07, p < 0.001), and these results showed that AUDA
enhanced the basal synaptic neurotransmission.
To determine whether AUDA treatment alters the
presynaptic efficiency of excitatory synaptic transmis-
sion, we tested the PPF in PFC slices. The ratio of
the fEPSP amplitude of the second fEPSP to the
amplitude of the first fEPSP was examined at 30, 60,
90, 120 and 150 interpulse intervals (Fig. 3c). There
was no difference in presynaptic glutamate release
probability with AUDA treatment in PFC neurons
(Fig. 3d, two-way ANOVA, effect of treatment F(3,76) = 0.19,
p = 0.92; effect of stimulus intensity F(4,76) = 34.2, p < 0.001;
interaction F(12,76) = 0.21, p =0.99). Hence the effect of
AUDA in PFC did not result in the alteration of presynaptic
probability of neurotransmitter release.
We further investigated the alteration of basal
excitatory synaptic transmission in PFC neurons by
AUDA treatment. PFC slices were made and whole-
cell recordings were made from the soma of visually
identified pyramidal-like neurons located in the PFC.
Figure 4a, b shows that AUDA (10 μM) treatment
resulted in a significantly higher mEPSCs amplitude
compared to vehicle state (p < 0.05). The mean
Fig. 1 The sEH inhibitor, AUDA, alters synaptic response in PFC pyramidal neurons. a Schematic illustration of prefrontal cortex slices and placement of
electrodes. The stimulating electrode was placed on layer II and the recording electrode was placed on layer V. Evoked EPSC was recorded of AMPA
EPSC which was isolated in the presence of NMDA antagonist (APV 50 μM) and GABAA receptor (bicuculline 10 μM) antagonists. (scale 40 ms, 50 pA).
Time course showed that treatment of 10 μM AUDA increased the EPSC amplitude. b Traces showed that the number of spikes evoked by a current
pulse during control/ACSF and perfusion with 10 μM AUDA (scale 100 ms ,20 pA). c The percentage of fEPSP response with 1 μM, 5 μM or 10 μM
AUDA treatment. ***p < 0.001 vs. vehicle control
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Fig. 3 The sEH inhibitor, AUDA, increases postsynaptic efficiency of I-O glutamatergic transmission but not presynaptic glutamate release in PFC
slice. a The I-O relationship was measured by the stimulation intensity and amplitude of fEPSP in the different concentration of 1 μM, 5 μM or
10 μM AUDA. b Mean value of I-O curves of glutamatergic transmission in PFC slices. c Sample traces were an average of 5-10 successive re-
sponses. The paired-pulse fEPSPs were evoked with intervals of 30 ms and 90 ms. Calibration; 50 pA, 30 ms. d Paired-pulse ratio was evoked at
30 ms, 60 ms, 90 ms, 120 ms, 150 ms intervals in the different concentration of AUDA. **p < 0.01, ***p < 0.001 vs. vehicle control
Fig. 2 Enhancement of synaptic response by EETs at prefrontal cortex synapse. a PFC slice was perfused with 14,15-EET (10 μM, n = 5), and the
percentage of fEPSPs response was measured. b The percentage of fEPSPs response was measured in the presence of vehicle combination with
AUDA or 14,15-EEZE in combination with AUDA. *p < 0.05 vs. control, **p < 0.01 vs. vehicle/AUDA group
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amplitude of the mEPSCs in the vehicle and AUDA
treated groups was 28.4 ± 5.9 pA and 62.0 ± 2.6 pA (p
< 0.05) respectively (Fig. 4c, d). The mean frequencies
of mEPSCs in the vehicle and AUDA treated groups
were 3.5 ± 0.3 Hz and 4,1 ± 0.4 Hz (Fig. 4b). These re-
sults demonstrated that enhancement of mEPSCs amp-
litude was observed in AUDA treated PFC slices, and the
frequency of mEPSCs was not affected.
AUDA enhances the long term potentiation (LTP) in the
PFC neurons
We investigated if sEH inhibition was required for, or in-
volved in, long term potentiation. We confirmed that ap-
plied high frequency stimulation (3 times for 1 sec at
100Hz stimuli separated by interval of 1 min; HFS) in-
duced long term potentiation in PFC neurons. As shown
in Fig. 5a, we used HFS protocol successfully induced
LTP. The degree of HFS-induced LTP was enhanced in
the presence of AUDA (Fig. 5b). We further compared
the amplitude of synapse at 10 or 60 min following tet-
anus HFS treatment in the absence or presence of
AUDA. The results showed a higher response for fEPSPs
at 10 min after HFS (vehicle: 126.3 ± 4.8 % of baseline,
n = 10 from 5 rats. AUDA: 180.3 ± 3.5 % of baseline,
n = 10 from 6 rats.) which maintained LTP at 60 min
after HFS (vehicle: 145.2 ± 7.4 % of baseline, n = 10 from
5 rats. AUDA: 172.1 ± 6.3 % of baseline, n = 10 from 6
rats) in the presence of AUDA (Fig. 5c, d). The results
suggest that AUDA can modulate synaptic efficiency to
facilitate the formation of and subsequently maintain
LTP (p < 0.01).
The expression of glutamate receptors is increased by the
inhibition of sEH
PFC glutamatergic neurotransmission is increased by
inhibiting sEH. This may be caused by the alteration
of glutamate receptor expression and function
[34–37]. We determined whether the expression of
AMPA receptors and NMDA receptors were altered
by AUDA. Rats were decapitated and PFC slices were
prepared. Slices were incubated with AUDA (10 μM)
for 10 min and washed to remove the drug. The protein
levels of the NMDA receptor were: NR1 (121.1 ± 6.6 % of
vehicle, n = 5), NR2A (158.3 ± 13.7 % of vehicle, n = 5) and
NR2B (135.2 ± 9.3 % of vehicle, n = 5). The levels of
Fig. 4 Enhancement of miniature excitatory postsynaptic current (mEPSC) amplitude in the PFC neurons by AUDA treatment. a Sample traces of
mEPSCs were taken from brainslices of vehicle control, AUDA treatment in PFC neurons. mEPSCs were recorded in the PFC neurons at a holding
potential of -70 mV in the presence of TTX (1 μM). Calibration: 50 pA, 100 ms. (b and c) The summary frequency and amplitude were measured
for vehicle control and AUDA groups. (d) The AUDA-induced changes were measured in percentage of frequency-/amplitude- of mEPSCs response at
10 μM of AUDA *p < 0.05 vs. vehicle control
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AMPA receptor GluR1 subunit (167.3 ± 10.4 % of control,
n = 5) and GluR2 subunit (129.9 ± 10.9 % of vehicle, n = 5)
were significantly higher in the AUDA-exposed than in
the Vehicle control state (p < 0.05 or p < 0.01). The dopa-
mine D2 receptor has been reported to be able to
contribute to the enhanced synaptic efficacy of the hippo-
campus by co-treating with cocaine and high frequency
stimulation [38]. We also found that AUDA treatment sig-
nificantly increased the protein level of the dopamine D2
receptor (n = 5) (Fig. 6a, b) (p < 0.05).
Fig. 5 sEH inhibitor, AUDA, facilitates LTP in PFC slice. a The graph represents the mean ± SEM slope of fEPSPs plotted against time. Applied with
3× high-frequency stimulation of 100 Hz for 1 s induced LTP. b In the presence of 1 μM AUDA, the enhancement of LTP was observed. c
Comparison of fEPSPs slope potentiation 10 min after tetanus in the absence or presence AUDA is shown. d Comparison of fEPSPs slope potentiation
60 min after tetanus in the absence or presence AUDA is shown. **p < 0.01 vs. vehicle control
Fig. 6 Synaptic receptors expression in PFC slices could be increased by the sEH inhibitor, AUDA. a The PFC slices were incubated with AUDA
(10 μM) for 10 min and then washed to remove AUDA. One hour later, homogenate from the PFC was prepared and blotted with antibodies
AMPA receptors subunit GluR1, GluR2, NMDA receptor subunits NR1, NR2A, NR2B and dopamine receptor D2 in the PFC slices. b The bar graph
showed the normalized band intensity of synaptic receptors in PFC slice. *p < 0.05, **p < 0.01 vs. vehicle control
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One possibility for the increase in NR1, NR2A, NR2B,
GluR1, GluR2 levels is the increment in total protein ex-
pression. We therefore performed RT-PCR and real time
qPCR to measure NR1, NR2A, NR2B, GluR1, GluR2
mRNA in tissue homogenates from PFC. By using RT-
PCR, the mRNA levels of NR1, NR2A, NR2B, GluR1,
GluR2 were: NR1 (95.3 ± 6.6 % of vehicle, n = 3), NR2A
(97.1 ± 1.4 % of vehicle, n = 3) and NR2B (105.2 ± 7.4 % of
vehicle, n = 3). The levels of GluR1 (98.3 ± 7.9 % of
vehicle, n = 3) and GluR2 (110.3 ± 4.9 % of vehicle,
n = 3) (Fig. 7a, b). Real-Time qPCR measured NR1
(96.6 ± 3.5 % of vehicle, n = 3), NR2A (112.8 ± 16.5 %
of vehicle, n = 3) and NR2B (93.2 ± 12.9 % of vehicle,
n = 3). The levels of GluR1 (104.6 ± 4.9 % of vehicle, n
= 3) and GluR2 (98.3 ± 16.9 % of vehicle, n = 3) (Fig. 7c).
The mRNA levels of NR1, NR2A, NR2B, GluR1, GluR2
examination showed no changes after AUDA treatment
compared to vehicle control group.
We further confirmed that the increased protein
levels are due to post-translational modification. We
examined the phosphorylation of NR2B, GluR1, GluR2 in
the PFC region treatment with AUDA. In the presence of
AUDA increased NR2B phosphorylation (139.9 ±
9.9 % of vehicle, n = 4), GluR1phosphorylation (184.2
± 7.6 % of vehicle, n = 4) and GluR2 phosphorylation
(119.4 ± 4.1 % of vehicle, n = 4) (Fig.8).
We wished to explore the possible signal pathway
underlying AUDA-mediated enhancement of PFC glu-
tamatergic neurotransmission. Many studies have
demonstrated that the EETs attenuated NF-κ B activa-
tion and increased PI3K/Akt and p42/p44 MAPK sig-
naling in endothelial cells and cardiomyocytes [39].
Thus sEH inhibition may increase the levels of EETs
with subsequent activation of ERK44/42 and modula-
tion synaptic plasticity in the PFC area. As shown in
9A, the phosphorylated levels of ERK44 (140.8 ±
10.5 %, n = 5 ) and ERK42 (158.1 ± 14.7 %, n = 5) were
significantly increased by AUDA treatment compared
with vehicle control (p < 0.05) (Fig. 9a). The total
ERKs did not change as a result of AUDA-treatment
compared with vehicle control. These data indicated
that AUDA could induce ERK44/42 activation in PFC
region.
Our results demonstrated that the degree of HFS-
induced LTP was enhanced in the presence of AUDA
(Fig. 5b). We therefore tested whether AUDA combin-
ation with HFS could further induce ERK44/42 activa-
tion in PFC region. The phosphorylated degree of
Fig. 7 The sEH inhibitor AUDA does not affect the total amount of NR1, NR2A, NR2B, GluR1, GluR2 mRNA levels. a, b Total RNA was isolated from
the PFC slices by treating with AUDA and mRNA expression for NR1, NR2A, NR2B, GluR1, GluR2 were analyzed with RT-PCR and (c) Real-Time
qPCR. The mRNA expression for β-actin was used as an internal control
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ERK44/42 (ERK44: 123.1 ± 4.7 % n = 5; ERK42: 153.6 ±
8.4 %, n = 5 ) was increased with LTP. The phosphory-
lated levels of ERK44/42 were further increased in the
presence of AUDA combination with HFS-induced LTP
protocol (ERK44: 159.8 ± 10.3 % n = 5; ERK42: 179.6 ±
7.5 %, n = 5 ) (Fig. 9b). In addition, COX2 has been re-
ported to be implicated in long-term potentiation [40].
Here we demonstrated that there was no difference in
the level of COX-2 normalized with GAPDH between
vehicle control state and AUDA-treated groups (106.4 ±
13.2 % of vehicle, n = 3 ) (Fig. 9c) (p > 0.05).
Discussion
In the present study, we provided evidence that sEHI en-
hanced the amplitude of evoked EPSCs and mEPSCs re-
sponses in PFC synapses by using whole-cell patch
clamp recordings. Extracellular recordings consistency
revealed increased fEPSPs and increased input-output
plots in a dose dependent manner after AUDA treat-
ment at PFC synapse from brain slices. Plasticity PPF is a
neurotransmitter efficacy index of presynapse released
probability [41]. An observed unchanged PPF, coupled with
increased fEPSPs suggests alteration of postsynaptic glu-
tamate neurotransmission in sEHI treated neurons. More-
over, sEHI facilitated a HFS-induced LTP. Finally, the
protein levels of GluR1, GluR2, NR2A and NR2B were in-
creased after treatment with sEHI AUDA. The AUDA fur-
ther increases the LTP-induced ERK phosphorylation.
These results provide new insights into the role that sEHI
may play in the regulation of synaptic efficacy in the PFC
area.
A report has demonstrated sEH specific expression in
pyramidal neuron of layer V in the dorsomedial cerebral
cortex [13]. It is still unknown how sEH exerts its effects
in modulating the basal synaptic responses. Here we
demonstrated that the sEH inhibitor, AUDA, induced the
enhancement of synaptic neurotransmission. Enhanced
levels of EETs resulting from sEH inhibition have been re-
ported [42, 43]. We applied the 14, 15-EET also increases
the fEPSPs response. The enhancement of postsynaptic re-
sponse induced by sEH inhibitor, AUDA is blocked by se-
lective EET antagonist. Thus sEH inhibitor causes the
Fig. 8 The sEH inhibitor AUDA increases the phosphorylation of protein levels by AUDA. a The tissue lysate of PFC area was prepared and blotted
with antibodies against the phosphorylated Ser1303 on NR2B, phosphorylated Ser831 on GluR1 and phosphorylated Tyr876 on GluR2. b The bar
graph showed the normalized band intensity of phosphorylated synaptic receptors in PFC slice. *p <0.05, **p < 0.01 vs. vehicle control
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levels of EETs to increase and thereby enhances the syn-
aptic excitatory response in the PFC region. Our results
showed that the sEH inhibition enhanced the amplitude
of evoked EPSCs and mEPSCs responses, but not PPF in
PFC synapses. Moreover, sEH inhibition induced the in-
crease of LTP magnitude in PFC synapses. These results
suggest that sEH inhibition affects postsynaptic efficacy
and is beneficial for maintaining LTP.
AMPA receptors and NMDA receptors have been con-
sidered as the major ionic glutamate receptors that are as-
sociated with excitatory neurotransmission and the
mediated the LTP in the brain [22, 23, 44]. The synaptic
response increment by sEH inhibition could be due to the
increase of neurotransmitter release from presynaptic or
increase in the number of glutamate postsynaptic recep-
tors. Our electrophysiology data showed the PPF did not
change by sEH inhibitor treatment, suggesting that sEH
inhibitor did not alter the presynaptic neurotransmission
at PFC synapse. Furthermore, we observed that inhibition
of sEH at the PFC synapse enhances the protein levels of
the NMDA receptor NR1 subunit, NR2A subunit and
NR2B subunit; AMPA receptor GluR1 subunit, GluR2 sub-
unit in the PFC region. Thus sEH inhibitor increases synap-
tic response mostly via altering the number of glutamate
postsynaptic receptors. The altered protein levels of AMPA
receptors and NMDA receptors by inhibiting of sEH did
not enhance mRNA level of GluR1, GluR2, NR1 NR2A and
NR2B in the PFC region. Our data further revealed that
sEH inhibitor resulted in increased NR2B, GluR1 and
GluR2 phosphorylation state, suggesting that post-
translational modification is involved in sEH inhibitor al-
tered synaptic response. The enhancement of phosphory-
lated protein levels is required for surface glutamate
receptors stability. The phosphorylated protein of glutamate
Fig. 9 The sEH inhibitor AUDA induced the phosphorylation of ERK in PFC slices. a The PFC slices were incubated with AUDA (10 μM) for 10 min
and then washed to remove AUDA. One hour later, homogenate from the PFC was prepared and blotted with antibodies directly against the
active form of ERKs. AUDA-induced increase of ERKs phosphorylation in the PFC slices is shown. AUDA treatment increased the phosphorylated
levels of ERK42 and ERK44 relative to the vehicle controls (ACSF). No change was observed when the cellular extract was blotted with an antibody
that recognizes total ERKs, suggesting that the observed pERKs increments were not due to an increase in the total amount of ERKs. b Here
shows the phosphorylated levels of ERK42 and ERK44 among the vehicle control, vehicle/HFS and AUDA/HFS groups. c The homogenate from
the PFC following AUDA treatment was prepared and blotted with antibodies directly against the COX-2. GAPDH was the internal control *p < 0.05,
**p < 0.01 vs. vehicle control; #p <0.05 vs. vehicle HFS group
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receptors also involved in regulation of NMDA receptors
and AMPA receptors function [45, 46]. Further studies are
needed to confirm how the phosphorylated protein in
modulation of synaptic plasticity by sEH inhibition.
We investigated the molecular pathway under sEH
inhibition treatment in PFC region. Previous studies
demonstrated that sEH inhibition enhanced levels of
EETs and increased PI3K/Akt and p42/p44 MAPK sig-
naling in endothelial cells, cardiomyocytes and diabetic
nephropathy disease [39, 42, 43, 47]. Additionally,
MAPKs pathway and phosphorylated level of ERKs are
classically required for NMDA-dependent LTP and long-
term memory [48–52]. Our data showed that the phos-
phorylated level of ERKs was significantly increased after
LTP. We also found that the sEH inhibitor AUDA not
only induced an increase in phosphorylated ERKs in the
mPFC slices, but also augmented LTP response, which
further increased the phosphorylated ERK; thus, en-
hanced LTP and potentiated activation of ERKs which
delivers glutamate receptors into the PFC post-synapse
by treatment with sEH inhibition. Dopamine D2 recep-
tors have been reported to be involved in cocaine facili-
tated protein synthesis dependent LTP [38, 48]. Our
results demonstrated a sEHI AUDA-induced increase in
dopamine D2 receptor activation in the PFC. Thus, the
effects of sEHI AUDA could also be due to activation of
D2 receptors that facilitates the formation and continu-
ation of LTP. In addition, cyclooxygenase 2 (COX-2) has
been reported to be required for synaptic plasticity and
acquisition of memory process [40, 51]. We found that
the protein level of COX-2, as detected by Western
Blotting, showed no difference between sEH inhibition
treatment and vehicle control in PFC slices. We know
that the prefrontal cortex is important for emotional
memory and experience memory [53–57]. Here we dem-
onstrated that sEHI AUDA induced synaptic related mo-
lecular changes in NMDA receptor subunits NR1, NR2A
and NR2B; and AMPA receptor subunits GluR1, GluR2;
and in the dopamine D2 receptor. sEHI AUDA contrib-
utes to the degree of HFS-induced LTP in the PFC re-
gion. These findings could also suggest that synaptic
properties of sEHI AUDA in PFC could lead to the
modulation of learning and memory.
Additionally, animal studies have shown that acute or
chronic pre-administration of sEH inhibitor could pro-
tect infarct size region and improve the neurodeficit
score which damaged by cerebral ischemia [4, 58]. The
glutamate transmission is dramatically increased during
ischemia [59]. Preconditioning by treated with glutamate
prevented oxygen-glucose deprivation (OGD)-induced
neuronal injury blocked by AMPA receptor antagonist
and NMDA receptor antagonist in primary cultured
cortical neurons [60]. Our finding demonstrated that
AUDA-induced the enhancement of glutamatergic
neurotransmission in PFC area and other studies have
shown OGD increased massive glutamatergic neuro-
transmission. Thus the underlying mechanisms of the
neuronal protective effect of AUDA on stroke or how
AUDA mediates regulation of vascular function or exci-
tatory transmission still need to be assessed. The role of
AUDA may regulate different responses underlie basal
condition and pathological condition. In the present
study, we observed that AUDA enhanced glutamatergic
transmission and LTP in PFC area may be beneficial to
learning and memory.
In summary, we showed that sEH inhibition induced an
enhancement of PFC neuronal synaptic neurotransmis-
sion. This enhancement of synaptic neurotransmission is
associated with an enhanced postsynaptic glutamatergic
receptor and postsynaptic glutamatergic receptor medi-
ated synaptic response. By contrast, the paired-pulse ratio
is not changed after inhibition of sEH activity. The pre-
synaptic mechanism is not involved in sEH inhibitor-
induction of synaptic response. Furthermore, enhanced
LTP may be via ERK phosphorylation resulting from the
delivery of glutamate receptors into the PFC by post-
synapse by treatment with AUDA. Our study provides a
foundation for understanding PFC related synaptic effi-
cacy and PFC related cognitive functioning with respect to
learning and memory.
Conclusions
We first report that sEH inhibitor mediated excitatory
neurotransmission in the PFC area. Inhibition of sEH en-
hances LTP which through the ERK phosphorylation
resulting from the delivery of glutamate receptors into the
PFC area. It is suggested that inhibition of sEH may
modulate the synaptic function and learning memory
formation.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
HC Lin conceived and designed the experiments. HF Wu, HJ Yen, HC Lin, CC
Huang, YC Lee performed the experiments. HF Wu, HC Lin, HJ Yen analyzed
the data. SZ Wu, TS Lee, CC Huang, YC Lee contributed reagents/materials/
analysis tools. HF Wu and HC Lin wrote the paper. All authors read and
approved the final manuscript.
Acknowledgments
We thank Ya-Ting Hsu for carefully read on the first draft of manuscript. This
study was supported by grants MOST 103-2320-B-010 -014 -MY2, MOST
102-2321-B-010 -025, MOST 103-2321-B-010-016 from the Ministry of Science
and Technology of Taiwan. This study was also supported by Yen Tjing Ling
Medical Fundation (CI-104-13), Taiwan. CMFHR10466 from Chi-Mei Medical
Center, Tainan, Taiwan. Brain Research Center, National Yang-Ming University
and a grant from Ministry of Education, Aim for the Top University Plan,
Taiwan. The funding institutions of this study had no further role in the study
design, the collection, analysis, and interpretation of data, the writing of this
paper, or the decision to submit it for publication.
Wu et al. Journal of Biomedical Science  (2015) 22:94 Page 11 of 13
Author details
1Institute and Department of Physiology, School of Medicine, National
Yang-Ming University, Taipei 11221, Taiwan. 2Ph.D. Program for Neural
Regenerative Medicine, College of Medical Science and Technology, Taipei
Medical University, Taipei 11031, Taiwan. 3Center for Neurotrauma and
Neuroregeneration, Taipei Medical University, Taipei 11031, Taiwan.
4Department of Anesthesiology, Chi-Mei Medical Center, Tainan, Taiwan.
5Brain Research Center, National Yang-Ming University, Taipei 11221, Taiwan.
Received: 7 June 2015 Accepted: 9 October 2015
References
1. Johansson C, Stark A, Sandberg M, Ek B, Rask L, Meijer J. Tissue specific
basal expression of soluble murine epoxide hydrolase and effects of
clofibrate on the mRNA levels in extrahepatic tissues and liver. Arch Toxicol.
1995;70(1):61–3.
2. Koerner IP, Jacks R, DeBarber AE, Koop D, Mao P, Grant DF, et al.
Polymorphisms in the human soluble epoxide hydrolase gene EPHX2 linked
to neuronal survival after ischemic injury. J Neurosci. 2007;27(17):4642–9.
doi:10.1523/JNEUROSCI.0056-07.2007.
3. Rawal S, Morisseau C, Hammock BD, Shivachar AC. Differential subcellular
distribution and colocalization of the microsomal and soluble epoxide
hydrolases in cultured neonatal rat brain cortical astrocytes. J Neurosci Res.
2009;87(1):218–27. doi:10.1002/jnr.21827.
4. Zhang W, Koerner IP, Noppens R, Grafe M, Tsai HJ, Morisseau C, et al.
Soluble epoxide hydrolase: a novel therapeutic target in stroke. J Cerebral
Blood Flow Metab. 2007;27(12):1931–40. doi:10.1038/sj.jcbfm.9600494.
5. Marowsky A, Burgener J, Falck JR, Fritschy JM, Arand M. Distribution of
soluble and microsomal epoxide hydrolase in the mouse brain and its
contribution to cerebral epoxyeicosatrienoic acid metabolism. Neuroscience.
2009;163(2):646–61. doi:10.1016/j.neuroscience.2009.06.033.
6. Fang X, Kaduce TL, Weintraub NL, Harmon S, Teesch LM, Morisseau C, et al.
Pathways of epoxyeicosatrienoic acid metabolism in endothelial cells.
Implications for the vascular effects of soluble epoxide hydrolase inhibition.
J Biol Chem. 2001;276(18):14867–74. doi:10.1074/jbc.M011761200.
7. Inceoglu B, Jinks SL, Schmelzer KR, Waite T, Kim IH, Hammock BD. Inhibition
of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia
and mechanical allodynia in a rat model of inflammatory pain. Life Sci.
2006;79(24):2311–9. doi:10.1016/j.lfs.2006.07.031.
8. Schmelzer KR, Inceoglu B, Kubala L, Kim IH, Jinks SL, Eiserich JP, et al.
Enhancement of antinociception by coadministration of nonsteroidal
anti-inflammatory drugs and soluble epoxide hydrolase inhibitors. Proc Natl
Acad Sci U S A. 2006;103(37):13646–51. doi:10.1073/pnas.0605908103.
9. Zhao X, Yamamoto T, Newman JW, Kim IH, Watanabe T, Hammock BD,
et al. Soluble epoxide hydrolase inhibition protects the kidney from
hypertension-induced damage. J Am Soc Nephrol. 2004;15(5):1244–53.
10. Zhang W, Otsuka T, Sugo N, Ardeshiri A, Alhadid YK, Iliff JJ, et al. Soluble
epoxide hydrolase gene deletion is protective against experimental cerebral
ischemia. Stroke. 2008;39(7):2073–8. doi:10.1161/STROKEAHA.107.508325.
11. Iliff JJ, Jia J, Nelson J, Goyagi T, Klaus J, Alkayed NJ. Epoxyeicosanoid
signaling in CNS function and disease. Prostaglandins Other Lipid Mediat.
2010;91(3-4):68–84. doi:10.1016/j.prostaglandins.2009.06.004.
12. Sellers KW, Sun C, Diez-Freire C, Waki H, Morisseau C, Falck JR, et al. Novel
mechanism of brain soluble epoxide hydrolase-mediated blood pressure
regulation in the spontaneously hypertensive rat. FASEB J. 2005;19(6):626–8.
doi:10.1096/fj.04-3128fje.
13. Bianco RA, Agassandian K, Cassell MD, Spector AA, Sigmund CD.
Characterization of transgenic mice with neuron-specific expression of
soluble epoxide hydrolase. Brain Res. 2009;1291:60–72. doi:10.1016/
j.brainres.2009.07.060.
14. Luria A, Morisseau C, Tsai HJ, Yang J, Inceoglu B, De Taeye B, et al.
Alteration in plasma testosterone levels in male mice lacking soluble
epoxide hydrolase. Am J Physiol Endocrinol Metab. 2009;297(2):E375–83.
doi:10.1152/ajpendo.00131.2009.
15. Inceoglu B, Zolkowska D, Yoo HJ, Wagner KM, Yang J, Hackett E, et al. Epoxy
fatty acids and inhibition of the soluble epoxide hydrolase selectively
modulate GABA mediated neurotransmission to delay onset of seizures.
PLoS One. 2013;8(12):e80922. doi:10.1371/journal.pone.0080922.
16. Hung YW, Hung SW, Wu YC, Wong LK, Lai MT, Shih YH, et al. Soluble
epoxide hydrolase activity regulates inflammatory responses and seizure
generation in two mouse models of temporal lobe epilepsy. Brain Behav
Immun. 2014. doi:10.1016/j.bbi.2014.07.016.
17. Sisignano M, Park CK, Angioni C, Zhang DD, von Hehn C, Cobos EJ, et al.
5,6-EET is released upon neuronal activity and induces mechanical pain
hypersensitivity via TRPA1 on central afferent terminals. J Neurosci.
2012;32(18):6364–72. doi:10.1523/JNEUROSCI.5793-11.2012.
18. Niciu MJ, Kelmendi B, Sanacora G. Overview of glutamatergic
neurotransmission in the nervous system. Pharmacol Biochem Behav.
2012;100(4):656–64. doi:10.1016/j.pbb.2011.08.008.
19. Whitlock JR, Heynen AJ, Shuler MG, Bear MF. Learning induces long-term
potentiation in the hippocampus. Science. 2006;313(5790):1093–7.
doi:10.1126/science.1128134.
20. Bailey CH, Giustetto M, Huang YY, Hawkins RD, Kandel ER. Is heterosynaptic
modulation essential for stabilizing Hebbian plasticity and memory? Nat Rev
Neurosci. 2000;1(1):11–20. doi:10.1038/35036191.
21. Sacktor TC. PKMzeta, LTP maintenance, and the dynamic molecular biology
of memory storage. Prog Brain Res. 2008;169:27–40. doi:10.1016/S0079-
6123(07)00002-7.
22. Malenka RC. Synaptic plasticity and AMPA receptor trafficking. Ann N Y
Acad Sci. 2003;1003:1–11.
23. Foster KA, McLaughlin N, Edbauer D, Phillips M, Bolton A, Constantine-Paton
M, et al. Distinct roles of NR2A and NR2B cytoplasmic tails in long-
term potentiation. J Neurosci. 2010;30(7):2676–85. doi:10.1523/
JNEUROSCI.4022-09.2010.
24. Otmakhov N, Tao-Cheng JH, Carpenter S, Asrican B, Dosemeci A, Reese TS,
et al. Persistent accumulation of calcium/calmodulin-dependent protein
kinase II in dendritic spines after induction of NMDA receptor-dependent
chemical long-term potentiation. J Neurosci. 2004;24(42):9324–31.
doi:10.1523/JNEUROSCI.2350-04.2004.
25. Zhang YP, Holbro N, Oertner TG. Optical induction of plasticity at single
synapses reveals input-specific accumulation of alphaCaMKII. Proc Natl Acad
Sci U S A. 2008;105(33):12039–44. doi:10.1073/pnas.0802940105.
26. Eales KL, Palygin O, O’Loughlin T, Rasooli-Nejad S, Gaestel M, Muller J, et al.
The MK2/3 cascade regulates AMPAR trafficking and cognitive flexibility. Nat
Commun. 2014;5:4701. doi:10.1038/ncomms5701.
27. Racaniello M, Cardinale A, Mollinari C, D’Antuono M, De Chiara G, Tancredi
V, et al. Phosphorylation changes of CaMKII, ERK1/2, PKB/Akt kinases and
CREB activation during early long-term potentiation at Schaffer collateral-
CA1 mouse hippocampal synapses. Neurochem Res. 2010;35(2):239–46.
doi:10.1007/s11064-009-0047-0.
28. Raymond CR, Redman SJ, Crouch MF. The phosphoinositide 3-kinase and
p70 S6 kinase regulate long-term potentiation in hippocampal neurons.
Neuroscience. 2002;109(3):531–6.
29. Man HY, Wang Q, Lu WY, Ju W, Ahmadian G, Liu L, et al. Activation of PI3-
kinase is required for AMPA receptor insertion during LTP of mEPSCs in
cultured hippocampal neurons. Neuron. 2003;38(4):611–24.
30. Mitsushima D, Ishihara K, Sano A, Kessels HW, Takahashi T. Contextual
learning requires synaptic AMPA receptor delivery in the hippocampus.
Proc Natl Acad Sci U S A. 2011;108(30):12503–8. doi:10.1073/
pnas.1104558108.
31. Lin HC, Mao SC, Gean PW. Block of gamma-aminobutyric acid-A receptor
insertion in the amygdala impairs extinction of conditioned fear. Biol
Psychiatry. 2009;66(7):665–73. doi:10.1016/j.biopsych.2009.04.003.
32. Washburn MS, Moises HC. Electrophysiological and morphological
properties of rat basolateral amygdaloid neurons in vitro. J Neurosci.
1992;12(10):4066–79.
33. Hsiao YH, Kuo JR, Chen SH, Gean PW. Amelioration of social isolation-triggered
onset of early Alzheimer’s disease-related cognitive deficit by N-acetylcysteine
in a transgenic mouse model. Neurobiol Dis. 2012;45(3):1111–20.
doi:10.1016/j.nbd.2011.12.031.
34. Ahmad M, Polepalli JS, Goswami D, Yang X, Kaeser-Woo YJ, Sudhof TC, et al.
Postsynaptic complexin controls AMPA receptor exocytosis during LTP.
Neuron. 2012;73(2):260–7. doi:10.1016/j.neuron.2011.11.020.
35. Luscher C, Malenka RC. NMDA receptor-dependent long-term potentiation
and long-term depression (LTP/LTD). Cold Spring Harb Perspect Biol.
2012;4(6). doi:10.1101/cshperspect.a005710.
36. Makino H, Malinow R. AMPA receptor incorporation into synapses during
LTP: the role of lateral movement and exocytosis. Neuron. 2009;64(3):381–90.
doi:10.1016/j.neuron.2009.08.035.
37. Matsuda S, Kakegawa W, Budisantoso T, Nomura T, Kohda K, Yuzaki M.
Stargazin regulates AMPA receptor trafficking through adaptor protein
Wu et al. Journal of Biomedical Science  (2015) 22:94 Page 12 of 13
complexes during long-term depression. Nat Commun. 2013;4:2759.
doi:10.1038/ncomms3759.
38. Fole A, Miguens M, Higuera-Matas A, Alguacil LF, Ambrosio E, Del Olmo N.
Cocaine facilitates protein synthesis-dependent LTP: the role of
metabotropic glutamate receptors. Eur Neuropsychopharmacol.
2014;24(4):621–9. doi:10.1016/j.euroneuro.2013.10.013.
39. Deng Y, Theken KN, Lee CR. Cytochrome P450 epoxygenases, soluble
epoxide hydrolase, and the regulation of cardiovascular inflammation. J Mol
Cell Cardiol. 2010;48(2):331–41. doi:10.1016/j.yjmcc.2009.10.022.
40. Cowley TR, Fahey B, O’Mara SM. COX-2, but not COX-1, activity is necessary
for the induction of perforant path long-term potentiation and spatial
learning in vivo. Eur J Neurosci. 2008;27(11):2999–3008. doi:10.1111/j.1460-
9568.2008.06251.x.
41. Zucker RS, Regehr WG. Short-term synaptic plasticity. Annu Rev Physiol.
2002;64:355–405. doi:10.1146/annurev.physiol.64.092501.114547.
42. Liu Y, Zhang Y, Schmelzer K, Lee TS, Fang X, Zhu Y, et al. The
antiinflammatory effect of laminar flow: the role of PPARgamma,
epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc Natl Acad
Sci U S A. 2005;102(46):16747–52. doi:10.1073/pnas.0508081102.
43. Norwood S, Liao J, Hammock BD, Yang GY. Epoxyeicosatrienoic acids and
soluble epoxide hydrolase: potential therapeutic targets for inflammation
and its induced carcinogenesis. Am J Transl Res. 2010;2(4):447–57.
44. Malenka RC, Bear MF. LTP and LTD: an embarrassment of riches. Neuron.
2004;44(1):5–21. doi:10.1016/j.neuron.2004.09.012.
45. Soderling TR, Derkach VA. Postsynaptic protein phosphorylation and LTP.
Trends Neurosci. 2000;23(2):75–80.
46. Strack S, McNeill RB, Colbran RJ. Mechanism and regulation of calcium/
calmodulin-dependent protein kinase II targeting to the NR2B subunit of
the N-methyl-D-aspartate receptor. J Biol Chem. 2000;275(31):23798–806.
doi:10.1074/jbc.M001471200.
47. Chen G, Xu R, Wang Y, Wang P, Zhao G, Xu X, et al. Genetic disruption of
soluble epoxide hydrolase is protective against streptozotocin-induced
diabetic nephropathy. Am J Physiol Endocrinol Metab. 2012;303(5):E563–75.
doi:10.1152/ajpendo.00591.2011.
48. Del Olmo N, Higuera-Matas A, Miguens M, Garcia-Lecumberri C, Borcel E,
Solis JM, et al. Hippocampal synaptic plasticity and water maze learning in
cocaine self-administered rats. Ann N Y Acad Sci. 2006;1074:427–37.
doi:10.1196/annals.1369.043.
49. Selcher JC, Nekrasova T, Paylor R, Landreth GE, Sweatt JD. Mice lacking the
ERK1 isoform of MAP kinase are unimpaired in emotional learning. Learn
Mem. 2001;8(1):11–9. doi:10.1101/lm.37001.
50. Selcher JC, Weeber EJ, Christian J, Nekrasova T, Landreth GE, Sweatt JD. A
role for ERK MAP kinase in physiologic temporal integration in hippocampal
area CA1. Learn Mem. 2003;10(1):26–39. doi:10.1101/lm.51103.
51. Williams JH, Bliss TV. An in vitro study of the effect of lipoxygenase and
cyclo-oxygenase inhibitors of arachidonic acid on the induction and
maintenance of long-term potentiation in the hippocampus. Neurosci Lett.
1989;107(1-3):301–6.
52. Winder DG, Martin KC, Muzzio IA, Rohrer D, Chruscinski A, Kobilka B, et al.
ERK plays a regulatory role in induction of LTP by theta frequency
stimulation and its modulation by beta-adrenergic receptors. Neuron.
1999;24(3):715–26.
53. Akirav I, Maroun M. The role of the medial prefrontal cortex-amygdala
circuit in stress effects on the extinction of fear. Neural Plast.
2007;2007:30873. doi:10.1155/2007/30873.
54. Alkayed NJ, Birks EK, Hudetz AG, Roman RJ, Henderson L, Harder DR.
Inhibition of brain P-450 arachidonic acid epoxygenase decreases baseline
cerebral blood flow. Am J Physiol. 1996;271(4 Pt 2):H1541–6.
55. Das SR, Magnusson KR. Changes in expression of splice cassettes of NMDA
receptor GluN1 subunits within the frontal lobe and memory in mice
during aging. Behav Brain Res. 2011;222(1):122–33. doi:10.1016/
j.bbr.2011.03.045.
56. Devito LM, Eichenbaum H. Memory for the order of events in specific
sequences: contributions of the hippocampus and medial prefrontal cortex.
J Neurosci. 2011;31(9):3169–75. doi:10.1523/JNEUROSCI.4202-10.2011.
57. Radley JJ, Williams B, Sawchenko PE. Noradrenergic innervation of the
dorsal medial prefrontal cortex modulates hypothalamo-pituitary-adrenal
responses to acute emotional stress. J Neurosci. 2008;28(22):5806–16.
doi:10.1523/JNEUROSCI.0552-08.2008.
58. Dorrance AM, Rupp N, Pollock DM, Newman JW, Hammock BD, Imig JD. An
epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid
(AUDA), reduces ischemic cerebral infarct size in stroke-prone
spontaneously hypertensive rats. J Cardiovasc Pharmacol. 2005;46(6):842–8.
59. Fujimoto S, Katsuki H, Kume T, Kaneko S, Akaike A. Mechanisms of oxygen
glucose deprivation-induced glutamate release from cerebrocortical slice
cultures. Neurosci Res. 2004;50(2):179–87. doi:10.1016/j.neures.2004.06.013.
60. Lin CH, Chen PS, Gean PW. Glutamate preconditioning prevents neuronal
death induced by combined oxygen-glucose deprivation in cultured
cortical neurons. Eur J Pharmacol. 2008;589(1-3):85–93. doi:10.1016/
j.ejphar.2008.05.047.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Wu et al. Journal of Biomedical Science  (2015) 22:94 Page 13 of 13
